Fibroblast growth factor 1 - Phage Pharmaceuticals

Drug Profile

Fibroblast growth factor 1 - Phage Pharmaceuticals

Alternative Names: FGF-1 - Phage; Fibroblast growth factor 1 - Phage

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Phage Pharmaceuticals
  • Class Anti-ischaemics; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase Unknown Ear disorders
  • No development reported Wounds

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Wounds in USA
  • 21 Dec 2011 Investigation in Ear disorders in USA (unspecified route)
  • 21 Dec 2011 Phage Pharmaceuticals files an IND application with the FDA in US for Ear disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top